The Miami Entrepreneur

Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints

Read Time:9 Second

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson’s disease fell flat in a clinical trial.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Travelers’ stock suffers biggest selloff in 4 years after profit miss
Next post Nordic Streamer Viaplay Launches on Amazon’s Prime Video Channels in U.S., Following Shutdown of Its Own Service